Prostate cancer drugs aren't cheap, so if you're on such medication, you're probably looking for ways to cut the cost. Well, good news - we know one a way!
According to a new American study published in the Journal of Clinical Oncology, you can boost the efficiency of your prostate cancer medication by simply taking it with food.
The investigators behind the study found that taking Zytiga (abiraterone acetate) with a low-fat breakfast boosted its efficiency, which could make the drug more convenient and significantly cheaper. Keep reading for the full scoop.
Zytiga is the standard medicine for prostate cancer that’s spread and progressed despite hormonal therapy
A one-month supply of Zytiga costs R95 000 to R130 000 when bought wholesale, or just over R1.2m each year. Many prostate cancer
patients take the drug for two to three years.
Patients who take Zytiga are told to take four 250 mg pills first thing in the morning and then wait an hour before eating breakfast.
The healing secret big pharma doesn’t want you to know!
“I may be politically incorrect and stepping on the toes of big pharma, but, my test results for my aggressive prostate cancer in consistently getting better and better. I have gone from surgery, chemo and radiation suggestions to my doctor’s suggestion of wait-and-see, as improvement has been quite dramatic. I have only been on my daily regimen for 9 months.” ~ John Duffy
Click here to find out what is healing John.
Taking a lower dose of Zytiga with a light breakfast boosts its efficiency, new study confirms
The new study found that taking a quarter of the recommended dose with a low-fat
breakfast, such as a bowl of cereal with skim milk, was just as effective. As a result, this enabled patients to slash drug costs by 75%!
“The patient gets a simplified schedule, slightly more control over his daily life, the convenience of eating whenever he chooses and the opportunity to share the cost-savings with his insurance company,” said study lead author Dr Russell Szmulewitz, a prostate cancer specialist from the University of Chicago. “Taking this medicine while fasting is wasteful,” he added.
Dr Szmulewitz confirmed that combining the lower dose of Zytiga with food didn’t reduce the drug’s effectiveness. His team found that progression-free survival was identical for 34 patients who took the lower dose with food and 34 patients who took the recommended dose without food – about 8.6 months.
Overall, taking the lower dose with food reduced costs by as much as R3.5m per patients, the team said.
“Although it should be validated with a larger trial with more robust clinical endpoints, given the pharmaco-economic implications, these data warrant consideration by prescribers, payers and patients,” Dr Szmulewitz concluded.
Note: 5 of 1 vote